0209 Keytruda TNBC adcomm
BioCentury & Getty Images


Survival projections aren’t enough to sway ODAC to recommend Keytruda for new TNBC indications

Feb 9, 2021 | 11:59 PM GMT

FDA and its Oncology Drugs Advisory Committee want more survival data before supporting an accelerated approval of Keytruda as an adjuvant and neoadjuvant therapy for triple-negative breast cancer — a decision that

Read the full 599 word article

How to gain access

Continue reading with a
two-week free trial.